Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
Glenmark Pharmaceuticals LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:532296NSE Symbol: GLENMARKP/E(TTM):30.59
ISIN Demat:INE935A01035Div & Yield %:0.12EPS(TTM):66.4
Book Value(Rs):868.316327Market Cap ( Cr.):57316.4Face Value(Rs):1
    Change Company 
Date Headline
24-Sep-25 Glenmark inks license and collaboration agreement with Hengrui Pharma
24-Sep-25 Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Press Release
23-Sep-25 Glenmark Pharmaceuticals to conduct board meeting
23-Sep-25 Glenmark Pharmaceuticals Ltd - Glenmark Pharmaceuticals Limited - Record Date
22-Sep-25 Glenmark Pharmaceuticals fixes record date for interim dividend
19-Sep-25 Glenmark Pharmaceuticals receives affirmation in credit rating from CRISIL
19-Sep-25 Glenmark Pharmaceuticals Ltd - Announcement under Regulation 30 (LODR)-Credit Rating
15-Sep-25 Glenmark Pharma to transfer its consumer care biz to Glenmark Consumer Care
15-Sep-25 Glenmark Pharmaceuticals Ltd - Transfer Of The Companys Consumer Care Business
09-Sep-25 Ichnos Glenmark Innovation receives upfront payment of USD700 million
<< < 1 2 3 4   > >>